The Implications of Nanomedicine in Cancer Therapy: Cytotoxic and Apoptotic Effects of Selenium Nanoparticles on Human Leukemia Cell Lines

Document Type : Original Article

Authors

1 National Cancer Institute, Department of Pathology, Cairo University, Egypt

2 Medical biotechnology, college of biotechnology , MUST

3 Faculty of Postgraduate Studies for nanotechnology, Cairo university.

4 Clinical pathology department, faculty of medicine ASU

5 Department of Molecular Diagnostics, Genetic Engineering, and Biotechnology Research Institute, University of Sadat City, Egypt.

6 Genetic Engineering, and Biotechnology Research Institute, Department of Molecular Diagnostics, University of Sadat City, Egypt.

Abstract

Background and objective: Selenium nanoparticles (SeNPs) have been observed to exhibit a pleiotropic action, whereby they induce apoptosis in tumor cells while simultaneously protecting healthy tissue cells against stress-induced cell death. The cells underwent a 24-hour treatment with SeNPs. This work objective was to the cytotoxic impacts of a specific selenium nanoparticle examination as a possible nanomedicine anticancer agent in inducing apoptosis in human leukemia cell lines.
Methodology: The MTT test was utilized to conduct the assessment of cytotoxicity and cell viability. To gain insight into the molecular processes of apoptotic genes, namely Bcl-2, Bax, and Caspase3, their levels of expression were assessed using real-time reverse transcription polymerase chain reaction (RT-PCR).
Results: The IC50 values of selenium nanoparticles on HL-60, K-562, and HS-5 cell lines were determined to be 3.01 ± 0.29, 2.59 ± 0.33, and 439.4 ± 15.8 μg/mL, respectively. The assessment of gene expression levels demonstrated a significant reduction in the anti-apoptotic Bcl-2 gene, accompanied by an elevation in the pro-apoptotic Bax and caspase3 mRNA gene expressions.
Conclusion: This study presented preliminary findings about the notable antitumor efficacy of Selenium Nanoparticles against human leukemia cell lines.

Keywords

Main Subjects



Articles in Press, Accepted Manuscript
Available Online from 23 April 2025
  • Receive Date: 13 March 2025
  • Revise Date: 28 March 2025
  • Accept Date: 23 April 2025